Put companies on watchlist
Kezar Life Sciences
ISIN: US49372L1008
WKN: A2JPE7
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Kezar Life Sciences · ISIN: US49372L1008 · Business Wire (ID: 20241105464303)
05 November 2024 04:58PM

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)


Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors’ and officers’ possible violations of state laws.

If you own Kezar Life Sciences stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at tkennedy@glancylaw.com, or at 212-682-5340. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased and held.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact

Glancy Prongay & Murray LLP
Tom Kennedy, 212-682-5340
tkennedy@glancylaw.com
www.glancylaw.com

Visual performance / price development - Kezar Life Sciences
Smart analysis and research tools can be found here.
This publication was provided by our content partner Business Wire
BusinessWire
via BusinessWire - Newsfeed
BusinessWire ©2024
BusinessWire
Contact:
101 California Street, 20th Floor San Francisco, CA, 94111 United States
+1.415.986.4422